

## Supplementary file 1

Jafari et al., *BiolImpacts*, 2023, 13(1), 51-61

doi: 10.34172/bi.2022.23698

<http://bi.tbzmed.ac.ir/>


# Silibinin induces immunogenic cell death in cancer cells and enhances the induced immunogenicity by chemotherapy

Sevda Jafari<sup>1,2</sup>, Saba Heydarian<sup>1,2</sup>, Raymond Lai<sup>3</sup>, Elnaz Mehdizadeh Aghdam<sup>2</sup>, Ommoleila Molavi<sup>1,2\*</sup>

<sup>1</sup> Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

<sup>2</sup> Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

<sup>3</sup> Department of Laboratory Medicine & Pathology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Canada



**Fig. S1.** Combination therapy images obtained by Compusyn. (A) Combination of silibinin and DOX in B16 cells, (B) combination of silibinin and DOX in CT26 cells, and (C) combination of silibinin and OXP in CT26 cells.